Table 2. Summary of Ewing cell lines.

Cell Line	ATCC Designation	Tissue	Doubling Time (hours)	Diagnosis	Patient Info	EWS-FLI1 translocation t(11;22)(q24;q12)	FLI1-EWS Reciprocal Fusion	TP53	KDM1A mRNA Expression Levelg	STAG2 Statush,i
A673	ATCC® CRL-1598™	Musclea	25c	Ewing's Sarcomaa	15 year old femalea	Type 1 Fusiond	Detectabled	Non-functional (p.A119 frameshift)c,f	8.49 ± 1.29	Wildtype
RD-ES	ATCC® HTB-166™	Bonea	60k	Ewing's Sarcomaa	19 year old malea	Type 2 Fusione	Unknown	Mutant (p.R273C)f	5.66 ± 0.75	No Expression
TC32	N/A	Boneb	24c	PNETb	17 year old femaleb	Type 1 Fusione	Unknown	Functional (Wildtype)c	2.32 ± 0.23	I636sf
TC-71	N/A	Ileumc	21c	Ewing's Sarcomab	22 year old maleb	Type 1 Fusiond,e	Undetectabled	Non-functional (p.R213 nonsense)c,f	3.14 ± 0.50	Wildtype

^aATCC

^bChildren's Oncology Group (COG) Cell Culture and Xenograft Repository

^cMay, W.A., et al. Characterization and Drug Resistance Patterns of Ewing's Sarcoma Family Tumor Cell Lines. PLoS One. 2013; 8(12): e80060.

^dElzi, D.J., et al. The role of FLI-1-EWS, a fusion gene reciprocal to EWS-FLI-1, in Ewing sarcoma. Genes Cancer. 2015 Nov; 6(11–12): 452–461.

^eHuang, H.J., et al. R1507, an Anti-Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antibody, and EWS/FLI-1 siRNA in Ewing's Sarcoma: Convergence at the IGF/IGFR/Akt Axis. PLoS One. 2011; 6(10): e26060.

^fTirode, F., Sirdez, D., et al. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov. 2014 Nov; 4(11): 1342–1353.

^gPishas, P.I., et al. Therapeutic targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response. Molecular Cancer Therapeutics. 2018 Sep; 17(9): 1902–1916.

^hCrompton, B.D., et al [5]

ⁱBrohl, A.S., et al [4]

^kHyper Cell Line Database